KR102687425B1 - 변형 아데노바이러스 - Google Patents

변형 아데노바이러스 Download PDF

Info

Publication number
KR102687425B1
KR102687425B1 KR1020207026679A KR20207026679A KR102687425B1 KR 102687425 B1 KR102687425 B1 KR 102687425B1 KR 1020207026679 A KR1020207026679 A KR 1020207026679A KR 20207026679 A KR20207026679 A KR 20207026679A KR 102687425 B1 KR102687425 B1 KR 102687425B1
Authority
KR
South Korea
Prior art keywords
cancer
adenovirus
mutation
binding
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207026679A
Other languages
English (en)
Korean (ko)
Other versions
KR20200122346A (ko
Inventor
알란 파커
케르튤라 하니 우시
Original Assignee
유니버시티 칼리지 카디프 컨설턴츠 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 칼리지 카디프 컨설턴츠 리미티드 filed Critical 유니버시티 칼리지 카디프 컨설턴츠 리미티드
Publication of KR20200122346A publication Critical patent/KR20200122346A/ko
Application granted granted Critical
Publication of KR102687425B1 publication Critical patent/KR102687425B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020207026679A 2018-02-16 2019-02-13 변형 아데노바이러스 Active KR102687425B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1802539.5A GB201802539D0 (en) 2018-02-16 2018-02-16 Modified adenoviruses
GB1802539.5 2018-02-16
PCT/GB2019/050380 WO2019158914A1 (en) 2018-02-16 2019-02-13 Modified adenoviruses

Publications (2)

Publication Number Publication Date
KR20200122346A KR20200122346A (ko) 2020-10-27
KR102687425B1 true KR102687425B1 (ko) 2024-07-22

Family

ID=61783770

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207026679A Active KR102687425B1 (ko) 2018-02-16 2019-02-13 변형 아데노바이러스

Country Status (16)

Country Link
US (1) US12318418B2 (cg-RX-API-DMAC7.html)
EP (1) EP3737403B1 (cg-RX-API-DMAC7.html)
JP (3) JP7862138B2 (cg-RX-API-DMAC7.html)
KR (1) KR102687425B1 (cg-RX-API-DMAC7.html)
CN (2) CN118834841A (cg-RX-API-DMAC7.html)
AU (1) AU2019220607B2 (cg-RX-API-DMAC7.html)
CA (1) CA3090859C (cg-RX-API-DMAC7.html)
DK (1) DK3737403T5 (cg-RX-API-DMAC7.html)
ES (1) ES2968387T3 (cg-RX-API-DMAC7.html)
FI (1) FI3737403T3 (cg-RX-API-DMAC7.html)
GB (1) GB201802539D0 (cg-RX-API-DMAC7.html)
IL (1) IL276535B2 (cg-RX-API-DMAC7.html)
PL (1) PL3737403T3 (cg-RX-API-DMAC7.html)
PT (1) PT3737403T (cg-RX-API-DMAC7.html)
SG (1) SG11202007470QA (cg-RX-API-DMAC7.html)
WO (1) WO2019158914A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
GB201802539D0 (en) * 2018-02-16 2018-04-04 Univ College Cardiff Consultants Ltd Modified adenoviruses
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
EP3812465A1 (en) * 2019-10-21 2021-04-28 Universität Ulm Adenovirus comprising a modified adenovirus hexon protein
WO2021205364A1 (en) * 2020-04-07 2021-10-14 Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd. Engineered oncolytic adenovirus
CA3209730A1 (en) * 2021-03-29 2022-10-06 Alan Parker Modified adenovirus
GB202214580D0 (en) 2022-10-04 2022-11-16 Univ College Cardiff Consultants Ltd Adenoviral vector therapy
GB202314435D0 (en) 2023-09-20 2023-11-01 Univ College Cardiff Consultants Ltd Modified adenovirus
CN121203037B (zh) * 2025-09-26 2026-05-12 北京因诺惟康医药科技有限公司 基于整合素改造的特异性靶向心脏及肌肉的aav9优势突变体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009098492A2 (en) 2008-02-07 2009-08-13 Andrew Baker Modulation of adenoviral tropism

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1516055A4 (en) 2002-01-24 2007-08-08 Scripps Research Inst FIBER OPERATING MODIFICATIONS FOR EFFICIENT TARGETS
CA2519680A1 (en) * 2003-03-28 2004-11-18 The Scripps Research Institute Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
GB0520068D0 (en) * 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
ES2367227T3 (es) * 2007-03-14 2011-10-31 Institut Catala D'oncologia Adenovirus con mutaciones en el dominio de retención en el retículo endoplasmático de la proteína e3-19k y su utilización en el tratamiento del cáncer.
AU2011306846B2 (en) * 2010-09-24 2015-05-14 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
EP3247807B1 (en) 2015-01-20 2020-12-16 Adcure Biotechnologies, LLC. Detargeted adenovirus variants and related methods
GB201802539D0 (en) * 2018-02-16 2018-04-04 Univ College Cardiff Consultants Ltd Modified adenoviruses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009098492A2 (en) 2008-02-07 2009-08-13 Andrew Baker Modulation of adenoviral tropism

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Blood. vol. 108, no. 8, pp. 2554-2561.

Also Published As

Publication number Publication date
ES2968387T3 (es) 2024-05-09
CA3090859C (en) 2025-04-01
IL276535B1 (en) 2025-03-01
IL276535B2 (en) 2025-07-01
JP2024020345A (ja) 2024-02-14
JP2025081522A (ja) 2025-05-27
IL276535A (en) 2020-09-30
PL3737403T3 (pl) 2024-03-18
PT3737403T (pt) 2024-01-24
WO2019158914A1 (en) 2019-08-22
DK3737403T5 (da) 2024-08-26
JP2021513843A (ja) 2021-06-03
FI3737403T3 (fi) 2024-01-17
SG11202007470QA (en) 2020-09-29
CA3090859A1 (en) 2019-08-22
EP3737403A1 (en) 2020-11-18
JP7862138B2 (ja) 2026-05-19
CN112020368A (zh) 2020-12-01
AU2019220607A1 (en) 2020-09-17
CN118834841A (zh) 2024-10-25
EP3737403B1 (en) 2024-01-03
CN112020368B (zh) 2024-07-12
US20210100855A1 (en) 2021-04-08
KR20200122346A (ko) 2020-10-27
DK3737403T3 (da) 2024-01-22
US12318418B2 (en) 2025-06-03
AU2019220607B2 (en) 2024-02-15
GB201802539D0 (en) 2018-04-04

Similar Documents

Publication Publication Date Title
EP3737403B1 (en) Modified adenoviruses
US11419926B2 (en) Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
EP2486137B1 (en) Replication-competent ad11p based viral vectors
JP7066812B2 (ja) 癌を治療するための治療用組成物及び使用方法
JP3556666B2 (ja) 新形成の治療及び予防のための細胞障害ウイルス
JP5075839B2 (ja) 癌の処置のための腫瘍崩壊性アデノウイルス
US6635244B2 (en) Adenovirus E1B-55K single amino acid mutants and methods of use
HK40030481A (en) Modified adenoviruses
HK40030481B (en) Modified adenoviruses
WO2020166727A1 (ja) ヒト35型アデノウイルスを基板とした腫瘍溶解性ウイルス
WO2024074825A1 (en) Adenoviral vector therapy
JP2024512985A (ja) 改変アデノウイルス
Stepanenko et al. Potency-enhancing mutations in E3-19K and i-leader increase the cytolytic activity of the PH20/SPAM1-armed oncolytic adenovirus Ad5Δ24RGD
JP2003250579A (ja) 細胞特異的発現複製ベクター
EP3997106A1 (en) Oncolytic non-human adenoviruses and uses thereof
KR20050060175A (ko) 저산소하에서 작동되는 프로모터를 가진 암 용해성아데노바이러스 및 이를 포함하는 항암조성물
CA2627638A1 (en) Conditionally replicating viruses and methods for cancer virotherapy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000